证券代码：300501 证券简称：海顺新材 公告编号：2025-093 债券代码：123183 债券简称：海顺转债 上海海顺新型药用包装材料股份有限公司 第五届董事会第四十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2025年10月17日以电话、微信、电子邮件等方式发出召开第五届董 事会第四十二次会议的通知。 2、会议于2025年10月28日在公司大会议室召开，采取现场会议加 通讯表决的方式进行表决。 3、本次董事会应到7人，现场会议出席董事6人，分别为林武辉、 朱秀梅、黄勤、王琳琳、郭珣、马石泓，以通讯方式出席董事1人， 为林鑫。 4、本次董事会由董事长林武辉先生主持，公司监事、高级管理人 员列席会议。 5、本次董事会会议的召集、召开和表决程序符合《公司法》等法 律、法规及《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 经与会董事认真审议，通过了以下议案： 1、审议《关于<2025 年第三季度报告>的议案》 公司编制的《2025 年第三季 ...

海顺新材公告，第三季度营收为2.65亿元，下降4.00%；净利润为2154.74万元，下降1.44%。前三季度 营收为8.23亿元，下降0.42%；净利润为4866.55万元，下降38.96%。 ...

Financial Performance - Q3 2025 revenue was CNY 265,258,563.69, a decrease of 4.00% year-over-year[6] - Net profit attributable to shareholders was CNY 21,547,375.35, down 1.44% compared to the same period last year[6] - Net profit excluding non-recurring items dropped by 65.43% to CNY 6,634,407.68[6] - Total profit decreased to ¥62,511,546.76, down 38.75% year-over-year, attributed to increased depreciation from fixed asset transfers and higher R&D expenses[10] - Net profit for the period was ¥54,416,274.80, representing a decline of 35.99% compared to the previous year[10] - Total operating revenue for the current period is ¥823,004,651.62, a decrease of 0.5% from ¥826,447,909.29 in the previous period[19] - Total operating costs increased to ¥815,792,926.85, up 10% from ¥741,453,727.58 in the previous period[19] - Net profit for the current period is ¥54,416,274.80, down 36% from ¥85,016,205.39 in the previous period[20] - Basic and diluted earnings per share decreased to ¥0.26 from ¥0.42 in the previous period[21] Cash Flow - Cash flow from operating activities decreased significantly by 86.53% to CNY 17,717,038.09[6] - Cash flow from operating activities saw a significant drop to ¥17,717,038.09, down 86.53% year-over-year, due to reduced cash receipts from sales[11] - Cash inflow from investment activities surged to ¥867,618,898.51, an increase of 199.48%, driven by stock disposals and dividends from joint ventures[11] - Cash outflow for investment activities rose to ¥904,053,524.66, up 70.84%, primarily due to increased purchases of stocks and financial products[11] - Cash flow from investing activities resulted in a net outflow of ¥36,434,626.15, compared to a net outflow of ¥239,482,060.20 in the previous period[22] - Cash flow from financing activities showed a net outflow of ¥12,230,658.73, improving from a net outflow of ¥224,669,581.83 in the previous period[22] - The ending balance of cash and cash equivalents is ¥294,168,413.55, down from ¥370,076,129.53 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,867,316,553.71, a decrease of 0.64% from the previous year[6] - The company's total assets decreased from CNY 2,885,699,417.44 to CNY 2,867,316,553.71, a decline of approximately 0.63%[16] - Current assets increased slightly from CNY 1,118,881,798.69 to CNY 1,133,089,243.45, an increase of about 1.3%[16] - The company's cash and cash equivalents decreased from CNY 327,731,235.40 to CNY 297,000,055.31, a decrease of approximately 9.4%[16] - Short-term borrowings increased significantly from CNY 137,810,018.05 to CNY 194,034,555.56, an increase of about 40.6%[17] - Total liabilities increased from CNY 1,057,771,514.20 to CNY 1,105,736,886.46, an increase of approximately 4.5%[18] - The company's equity attributable to shareholders decreased from CNY 1,740,925,704.26 to CNY 1,668,520,755.19, a decline of about 4.1%[18] Receivables and Investments - The company reported a 40.84% increase in receivables financing, totaling CNY 111,090,221.30[9] - Other receivables surged by 407.58% to CNY 21,593,947.31, primarily due to acquisition-related payments[9] - Investment income increased significantly to ¥40,582,174.30, up 444.35% compared to the previous period, primarily due to stock trading gains and equity transfer from subsidiaries[10] - Profit from joint ventures rose to ¥15,566,287.80, reflecting a 117.91% increase, mainly from equity transfer gains from Shanghai Jiucheng Packaging Co., Ltd.[10] - The company's long-term investments decreased from CNY 201,845,848.77 to CNY 187,301,636.57, a decline of approximately 7.2%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,499, with the largest shareholder holding 29.98% of the shares[13] - The company reported a total of 10,088,375 shares held in the repurchase account, accounting for 5.21% of the total share capital[16] Other Information - The company's basic earnings per share remained stable at CNY 0.12, but diluted earnings per share also stayed at CNY 0.12[6] - The third quarter financial report of Shanghai Haishun New Pharmaceutical Packaging Materials Co., Ltd. has not been audited[23] - The new accounting standards will be implemented starting from 2025[23] - The financial statement items related to the first year of the new accounting standards will be adjusted at the beginning of the year[23]

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 会议召开时间：2025 年 10 月 30 日（星期四）15:00-16:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集：投资者可于 2025 年 10 月 30 日前访问网址 https://eseb.cn/1szYzX7Iwp2 或使用微信扫描下方小程序码进 行会前提问，公司将通过本次业绩说明会，在信息披露允许范 围内就投资者普遍关注的问题进行回答。 （www.ir-online.cn）举办上海海顺新型药用包装材料股份有限公司 2025年第三季度业绩说明会，与投资者进行沟通和交流，广泛听取投 资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2025年10月30日（星期四）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 董事长兼总 ...

Core Viewpoint - The company clarified that its functional films differ from those produced by Hengli, indicating no direct competition between the two [1] Company Strategy - The company is considering mergers and acquisitions (M&A) based on its core business, strategic direction, industry development, business synergy, and M&A costs [1] - Any potential M&A plans will comply with the disclosure requirements of the Shenzhen Stock Exchange's Growth Enterprise Market listing rules [1]

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届董事会第三十五次会议和第五届监事会第二十三次会议，审议 通过了《关于继续使用部分闲置募集资金进行现金管理的议案》，同 意延长可转换公司债券部分闲置募集资金进行现金管理的授权期限， 继续使用不超过人民币22,000万元的可转换公司债券部分闲置募集 资金进行现金管理。使用期限为自原到期之日即2025年4月10日起12 个月内进行滚动使用。除此之外，关于使用可转换公司债券闲置募集 资金进行现金管理的其他事宜保持不变。具体内容详见2025年3月27 日刊登在巨潮资讯网（http://www.cninfo.com.cn）的《关于继续使 用部分闲置募集资金进行现金管理的公告》（公告编号：2 ...

Core Viewpoint - The company aims to enhance performance and market share through cost reduction, efficiency improvement, capacity ramp-up, and increased R&D and market development efforts [1] Group 1 - The company plans to focus on cost reduction and efficiency enhancement [1] - The company intends to accelerate capacity ramp-up to meet market demand [1] - The company will increase investment in research and development and market expansion to capture market share [1] Group 2 - The company emphasizes the importance of improving performance and market value to facilitate debt-to-equity swaps [1] - The company advises stakeholders to refer to disclosed periodic reports for performance details [1]

Group 1 - The company, Haishun New Materials (300501.SZ), announced a share buyback program, having repurchased a total of 6,482,775 shares, which represents 3.35% of its current total share capital [1] - The highest transaction price during the buyback was 18.47 CNY per share, while the lowest was 13.50 CNY per share [1] - The total amount spent on the buyback was approximately 105.04 million CNY, excluding transaction fees [1]

证券日报网讯 10月9日晚间，海顺新材发布公告称，2024年10月10日，公司首次通过深圳证券交易所股 票交易系统以集中竞价交易方式回购公司股份。截至本公告披露日，公司本次回购股份方案已实施完 毕。公司通过深圳证券交易所股票交易系统以集中竞价交易方式回购公司股份累计6，482，775股，约 占公司总股本的3.35%。 （文章来源：证券日报） ...

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2025-084 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 关于回购股份进展暨回购完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年10月8日召开第五届董事会第二十七次会议，审议通过了《关 于以集中竞价交易方式回购股份方案的议案》，拟使用自有资金或自 筹资金以集中竞价交易方式回购公司人民币普通股（A股），回购的 公司股份用于可转换公司债券转股。本次回购股份资金总额不低于人 民币10,000万元（含），不超过人民币20,000万元（含），回购价格 上限为不超过人民币17.55元/股，本次回购股份的实施期限为自公司 董事会审议通过回购股份方案之日起12个月内。具体回购股份数量以 回购期限届满或回购实施完成时实际回购的股份数量为准。具体内容 详见公司于2024年10月10日在巨潮资讯网(www.cninfo.com.cn)上 ...